Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
Clinical trial NCT02097810 · COMPLETED
Trial details
- NCT number
- NCT02097810
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-28
- Primary completion
- 2020-06-02
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.